Sign inJoin waitlistJoin the waitlist

Tara Lin

Associate Professor of Medicine · University of Kansas School of Medicine

Credentials: · · · ·

History

University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present

University of Maryland and Medical Oncology Fellowship at Johns Hopkins
2003–2005
Internal Medicine
2000–2003
Liberal Arts, University of Virginia, Charlottesville, VA
Virginia Commonwealth Univ, Med Coll of Virginia
1996–2000
University of Virginia

Research

Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Journal of Clinical Oncology · 2019 · 557 citations

Joseph McGuirk
29 papers
Sunil Abhyankar
26 papers
Siddhartha Ganguly
25 papers
Gary Schiller
21 papers
Alice Mims
20 papers
Omar Aljitawi
20 papers
Maria Baer
16 papers
Uma Borate
16 papers
Anurag Singh
15 papers
Brian Druker
15 papers
William Blum
15 papers
JB
John Byrd
14 papers

Grants

Expanding Access and Enrollment to Precision Medicine Trials in Acute Myeloid Leukemia
National Cancer Institute · R50
Contact PI · $271.9K · University of Kansas Medical Center
2025–2030
The University of Kansas Cancer Center
National Cancer Institute · P30
Project lead · $1.4M · University of Kansas Medical Center
2012–2027
Chemotherapy Resistance in ALL: Role of the Bone Marrow Microenvironment
National Cancer Institute · K23
Contact PI · $699.8K · University of Kansas Medical Center
2012–2016

Clinical trials

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Principal investigator · Completed · Phase 1
Tara Lin
2016–2021
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Site PI · Recruiting · Phase 1
Celyad Oncology SA
2019–2035